Key result
Olmesartan 20 mg significantly improved carotid femoral pulse wave velocity (-1.6 vs -0.9 m/s, P=0.04) and oxidative stress compared to Telmisartan 40 mg over four weeks.
Why the study?
Does Olmesartan improve vascular hemodynamics, arterial stiffness, and oxidative stress compared to Telmisartan in patients with mild to moderate hypertension?
RCT (n=69)
Open-label
randomly allocated
Does Olmesartan improve vascular hemodynamics, arterial stiffness, and oxidative stress compared to Telmisartan in patients with mild to moderate hypertension?
Olmesartan may offer superior vascular and antioxidant benefits compared to Telmisartan in mild to moderate hypertension, independent of blood pressure lowering.
Answers are grounded in this paper and cite their sources.
Olmesartan may reduce arterial stiffness more than telmisartan in mild hypertension; extends ARB comparisons to vascular and oxidative endpoints.
Introduction . We studied the acute effects of Olmesartan and Telmisartan at baseline and at the end of four weeks on indices of hemodynamics (heart rate HR, blood pressure BP), vascular (carotid femoral pulse wave velocity cf PWV, digital arterial tone expressed as Reflection index RI, and endothelial dependent vasodilator response EDVR), and oxidative stress (serum Malondialdehyde MDA) in hypertensive patients. Materials and Methods . The eligible patients were randomly allocated to either 20 mg Olmesartan or 40 mg Telmisartan. Results . 40 subjects received Olmesartan, and 29 received Telmisartan. After four weeks of treatment the mean changes from baseline in the Olmesartan group versus Telmisartan group are SBP -9.8±10 versus -6.3±12 mm Hg, P=0.24; DBP -6.1±11 versus -4.2±12.5 mm Hg, P=0.55; cf PWV -1.6±1.2 versus -0.9±1.4 m/s, P=0.04; EDVR -8.2±5.2 versus -5.2±5.7%, P=0.04; and MDA -1.9±1.1 versus -1.2±1.2 η Mol/mL, P=0.03. Conclusion . Olmesartan showed a better improvement in cf PWV, EDVR, and MDA than Telmisartan with an identical reduction in blood pressure.
No takes yet. Share an insight, caveat, or question.
Pathapati et al. (2013) conducted an RCT in Mild to moderate hypertension (n=69). Olmesartan vs. Telmisartan 40 mg was evaluated on mean change from baseline in carotid femoral pulse wave velocity (cf PWV) (p=0.04). Olmesartan 20 mg significantly improved carotid femoral pulse wave velocity (-1.6 vs -0.9 m/s, P=0.04) and oxidative stress compared to Telmisartan 40 mg over four weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: